Katja Weisel
Impact in
- Hematology top 0.1%
- Multiple Myeloma Research and Treatments
- Oncology top 0.5%
- Peptidase Inhibition and Analysis
- CAR-T cell therapy research
- Cancer Treatment and Pharmacology
Papers in
- Hematology 297
- Multiple Myeloma Research and Treatments 286
- Oncology 189
- Cancer Treatment and Pharmacology 70
- Peptidase Inhibition and Analysis 66
- CAR-T cell therapy research 33
- Co-authors
- María‐Victoria MateosMeletios Α. DimopoulosVânia HungriaPieter SonneveldAjay K. NookaAndrew SpencerAntonio PalumboXiang Qin
- Journals
- Blood (62 papers)Journal of Clinical Oncology (56 papers)HemaSphere (19 papers)Blood Cancer Journal (9 papers)Cancers (7 papers)
- Partner nations
- GermanyUnited StatesSpain
In The Last Decade
Katja Weisel
311 papers receiving 5.6k citations
Hit Papers
Peers
Comparison fields: 5 of 116
- Hematology 4.3k
- Oncology 3.0k
- Genetics 711
- Molecular Biology 3.2k
- Immunology 634
Countries citing papers authored by Katja Weisel
This map shows the geographic impact of Katja Weisel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katja Weisel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katja Weisel more than expected).
Fields of papers citing papers by Katja Weisel
This network shows the impact of papers produced by Katja Weisel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katja Weisel. The network helps show where Katja Weisel may publish in the future.
Co-authors
The 25 scholars most cited alongside Katja Weisel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 2 | |
| 4 | 2024 | 0 | |
| 5 | 2024 | 0 | |
| 6 | 2024 | 8 | |
| 7 | 2024 | 4 | |
| 8 | 2023 | 4 | |
| 9 | 2023 | 2 | |
| 10 | 2022 | 84 | |
| 11 | 2021 | 24 | |
| 12 | 2021 | 7 | |
| 13 | 2020 | 24 | |
| 14 | 2020 | 7 | |
| 15 | Dreamm-4: evaluating safety and clinical activity of belantamab mafodotin (belamaf) in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (rrmm) | 2020 | 1 |
| 16 | 2017 | 1 | |
| 17 | 2017 | 1 | |
| 18 | THE STRATUS (MM-010) TRIAL: A SINGLE-ARM, PHASE 3B STUDY EVALUATING SAFETY AND EFFICACY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA | 2015 | 1 |
| 19 | Overall survival of patients with relapsed and refractory multiple myeloma: adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone vs. high-dose dexamethasone | 2014 | 1 |
| 20 | 2014 | 14 |
About Katja Weisel
Katja Weisel is a scholar working on Hematology, Oncology, Genetics, Molecular Biology and Pathology and Forensic Medicine, having authored 335 papers that have together received 5.7k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (286 papers), Protein Degradation and Inhibitors (117 papers), Cancer Treatment and Pharmacology (70 papers), Peptidase Inhibition and Analysis (66 papers), CAR-T cell therapy research (33 papers), Monoclonal and Polyclonal Antibodies Research (30 papers), Chronic Lymphocytic Leukemia Research (27 papers) and Cancer Mechanisms and Therapy (17 papers). The work is most often cited by research in Hematology (4.3k citations), Oncology (3.0k citations), Genetics (711 citations), Molecular Biology (3.2k citations) and Immunology (634 citations). Katja Weisel has collaborated with scholars based in Germany, United States and Spain. Frequent co-authors include María‐Victoria Mateos, Meletios Α. Dimopoulos, Vânia Hungria, Pieter Sonneveld, Ajay K. Nooka, Andrew Spencer, Antonio Palumbo, Xiang Qin, Jordan M. Schecter and Anita Zahlten‐Kumeli. Their work appears in journals such as Blood, Journal of Clinical Oncology, HemaSphere, Blood Cancer Journal and Cancers.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.